Otsuka Obtains U.S. FDA Fast Track Review For Dry AMD Oral Treatment
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA granted a fast track review of Otsuka's dry age-related macular degeneration oral treatment ACU-4429. Developed by Tokyo-based Otsuka Pharmaceutical and Bothell, WA-based biotech Acucela, ACU-4429 is in Phase II studies in the U.S. Utilizing Accuela proprietary visual cycle modulation technology, the compound is developed to prevent or inhibit the generation of toxic byproducts that can lead to degenerative eye conditions like dry AMD. (Click here for more - Japanese language